5231-89-0

Basic information

• Product Name: 3,4-DIAMINOCYCLOBUT-3-ENE-1,2-DIONE
• Synonyms: 3,4-DIAMINOCYCLOBUT-3-ENE-1,2-DIONE;3,4-Dioxocyclobut-1-en-1,2-diamine, 1,2-Diamino-3,4-dioxocyclobut-1-ene;Squaramide;1.2-Diaminocyclobuten-3.4-dion
• CAS NO: 5231-89-0
• Molecular Formula: C₄H₄N₂O₂
• Molecular Weight: 112.09
• Mol File: 5231-89-0.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 213.8 °C at 760 mmHg
• Flash Point: 83.1 °C
• Appearance: /
• Density: 1.638 g/cm³
• Vapor Pressure: 0.161mmHg at 25°C
• Refractive Index: 1.665
• PKA: -0.21±0.20(Predicted)
• CAS DataBase Reference: 3,4-DIAMINOCYCLOBUT-3-ENE-1,2-DIONE(CAS DataBase Reference)
• NIST Chemistry Reference: 3,4-DIAMINOCYCLOBUT-3-ENE-1,2-DIONE(5231-89-0)
• EPA Substance Registry System: 3,4-DIAMINOCYCLOBUT-3-ENE-1,2-DIONE(5231-89-0)

Safety Data

• Hazardous Substances Data: 5231-89-0(Hazardous Substances Data)

Usage

General Description

3,4-DIAMINOCYCLOBUT-3-ENE-1,2-DIONE is a chemical compound with the molecular formula C4H6N2O2. It is also known as 3,4-Diaminomaleimide and is a cyclic imide that contains a four-membered cyclobutene ring. It is a versatile building block for the synthesis of various functionalized heterocyclic compounds and is used as a reagent in organic synthesis. Due to its unique structure, it exhibits interesting reactivity and has been utilized in the development of novel pharmaceuticals and materials. 3,4-DIAMINOCYCLOBUT-3-ENE-1,2-DIONE is also a useful tool in the study of organic chemistry and has potential applications in medicinal chemistry and material science.

InChI:InChI=1/C4H4N2O2/c5-1-2(6)4(8)3(1)7/h5-6H2

Upstream product

• 5231-87-8 3,4-diethoxy-3-cyclobuten-1,2-dione 

Downstream Products

• 1426411-74-6 C₁₄H₈Cl₂N₄O₂ 

Relevant articles and documents

KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF

Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.

Amino substituted bisketenes: Generation, structure, and reactivity

Hitherto unknown diamino-substituted bisketenes with both free (14) and tethered (16) amino substituents have been generated by using laser flash photolysis for ring opening of the corresponding cyclobutenediones. The time-resolved kinetics of ring closur